Technical Analysis for BFFTF - Biofrontera Ag
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| See historical BFFTF trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | -17.52% | |
| Gapped Down | Weakness | -17.52% | |
| Narrow Range Bar | Range Contraction | -25.92% | |
| Gapped Up | Strength | -25.92% | |
| Volume Surge | Other | -24.59% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
Medicine Medical Specialties RTT Biopharmaceutical Diseases Organ Systems Dermatology Migraine Actinic Keratosis Photodynamic Therapy Carcinoma Keratosis Treatment Of Migraine
Medicine Medical Specialties RTT Biopharmaceutical Diseases Organ Systems Dermatology Migraine Actinic Keratosis Photodynamic Therapy Carcinoma Keratosis Treatment Of Migraine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|
| Indicator | Value |
|---|---|
| 52 Week High | 8.22 |
| 52 Week Low | 5.5049 |
| Average Volume | 12,049 |
| 200-Day Moving Average | 0.0000 |
| 50-Day Moving Average | 0.0000 |
| 20-Day Moving Average | 0.0000 |
| 10-Day Moving Average | 0.0000 |
| Average True Range | 0.0000 |
| ADX | 0.0 |
| +DI | 0.0000 |
| -DI | 0.0000 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.0000 |
| Lower Bollinger Band | 0.0000 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.0000 |
| MACD Line | 0.0000 |
| MACD Signal Line | 0.0000 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.6719 | ||||
| Resistance 3 (R3) | 5.6904 | 5.6533 | 5.6440 | ||
| Resistance 2 (R2) | 5.6533 | 5.6108 | 5.6440 | 5.6347 | |
| Resistance 1 (R1) | 5.5791 | 5.5845 | 5.5606 | 5.5606 | 5.6255 |
| Pivot Point | 5.5420 | 5.5420 | 5.5327 | 5.5327 | 5.5420 |
| Support 1 (S1) | 5.4678 | 5.4995 | 5.4493 | 5.4493 | 5.3843 |
| Support 2 (S2) | 5.4307 | 5.4732 | 5.4214 | 5.3751 | |
| Support 3 (S3) | 5.3565 | 5.4307 | 5.3658 | ||
| Support 4 (S4) | 5.3380 |
